FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Camlin Tierney

Research Profile

Chemicals & Drugs

Disorders

Concepts & Ideas

Viral Load

Living Beings

HIV-1
HIV

Procedures

Co-author Network

Publications

TOP 3
Xinyan Zhang; Hongyu Jiang; Gene Morse; Camlin Tierney; Mary Albrecht; Lisa M Demeter; Robin DiFrancesco; Carrie Dykes; David W Haas
Discordant associations between SLCO1B1 521T→C and plasma levels of ritonavir-boosted protease inhibitors in AIDS clinical trials group study A5146.
Heather J Ribaudo; Paul E Sax; Camlin Tierney; Ann C Collier; Eric S Daar; Margaret A Fischl; David W Haas; Katie Mollan; Gene D Morse
Impact of UGT1A1 Gilbert variant on discontinuation of ritonavir-boosted atazanavir in AIDS Clinical Trials Group Study A5202.
Katie Mollan; Paul E Sax; Camlin Tierney; Maya Balamane; Ronald J Bosch; Ann C Collier; Eric S Daar; Margaret A Fischl; David Katzenstein; Christina M Lalama
HIV-1 amino acid changes among participants with virologic failure: associations with first-line efavirenz or atazanavir plus ritonavir and disease status.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Camlin Tierney (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Xinyan Zhang; Hongyu Jiang; Gene Morse; Camlin Tierney; Mary Albrecht; Lisa M Demeter; Robin DiFrancesco; Carrie Dykes; David W Haas
Discordant associations between SLCO1B1 521T→C and plasma levels of ritonavir-boosted protease inhibitors in AIDS clinical trials group study A5146.
Therapeutic drug monitoring 2013;35(2):209-16.
2013: Heather J Ribaudo; Paul E Sax; Camlin Tierney; Ann C Collier; Eric S Daar; Margaret A Fischl; David W Haas; Katie Mollan; Gene D Morse
Impact of UGT1A1 Gilbert variant on discontinuation of ritonavir-boosted atazanavir in AIDS Clinical Trials Group Study A5202.
The Journal of infectious diseases 2013;207(3):420-5.
2012: Katie Mollan; Paul E Sax; Camlin Tierney; Maya Balamane; Ronald J Bosch; Ann C Collier; Eric S Daar; Margaret A Fischl; David Katzenstein; Christina M Lalama
HIV-1 amino acid changes among participants with virologic failure: associations with first-line efavirenz or atazanavir plus ritonavir and disease status.
The Journal of infectious diseases 2012;206(12):1920-30.
2012: Grace A McComsey; Kathleen Melbourne; Camlin Tierney; Anthony Bloom; Todd T Brown; Eric S Daar; Neal S Fedarko; Belinda Ha; Nasreen C Jahed; Douglas Kitch; Paul E Sax
Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir.
AIDS (London, England) 2012;26(11):1371-85.
2011: Paul E Sax; Karen Tashima; Camlin Tierney; William C Woodward; Chakra Budhathoki; Ann C Collier; Eric S Daar; Awny Farajallah; Judith Feinberg; Margaret A Fischl; Catherine Godfrey; Belinda Ha; Nasreen C Jahed; David Katzenstein; Katie Mollan; Robert L Murphy; Laurie Myers; James F Rooney
Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results.
The Journal of infectious diseases 2011;204(8):1191-201.
2011: Grace A McComsey; Kathleen Melbourne; Laurie Myers; Paul E Sax; Pablo Tebas; Camlin Tierney; Belinda Ha; Nasreen C Jahed; Douglas Kitch; Eric S Daar
Peripheral and central fat changes in subjects randomized to abacavir-lamivudine or tenofovir-emtricitabine with atazanavir-ritonavir or efavirenz: ACTG Study A5224s.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2011;53(2):185-96.
2011: Mary Albrecht; Carrie Dykes; Karin L Klingman; Gene D Morse; A Lisa Mukherjee; Camlin Tierney; Lisa M Demeter
A randomized clinical trial evaluating therapeutic drug monitoring (TDM) for protease inhibitor-based regimens in antiretroviral-experienced HIV-infected individuals: week 48 results of the A5146 study.
HIV clinical trials 2011;12(4):201-14.
2011: Grace A McComsey; Douglas Kitch; Eric S Daar; Camlin Tierney; Nasreen C Jahed; Pablo Tebas; Laurie Myers; Kathleen Melbourne; Belinda Ha; Paul E Sax
Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202.
The Journal of infectious diseases 2011;203(12):1791-801.
2011: Eric S Daar; Camlin Tierney; Margaret A Fischl; Paul E Sax; Katie Mollan; Chakra Budhathoki; Catherine Godfrey; Nasreen C Jahed; Laurie Myers; David Katzenstein; Awny Farajallah; James F Rooney; Keith A Pappa; William C Woodward; Kristine Patterson; Hector Bolivar; Constance A Benson; Ann C Collier
Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1.
Annals of internal medicine 2011;154(7):445-56.
2011: Beverly E Sha; Camlin Tierney; Susan E Cohn; Xin Sun; Robert W Coombs; Lisa M Frenkel; Spyros A Kalams; Francesca T Aweeka; Barbara Bastow; Arlene Bardeguez; Anne Kmack; Alice Stek
Postpartum viral load rebound in HIV-1-infected women treated with highly active antiretroviral therapy: AIDS Clinical Trials Group Protocol A5150.
HIV clinical trials 2011;12(1):9-23.
2010: Charles Flexner; Camlin Tierney; Robert Gross; Adriana S A Andrade; Christina Lalama; Susan H Eshleman; Judith Aberg; Ian Sanne; Teresa Parsons; Angela D M Kashuba; Susan L Rosenkranz; Anne Kmack; Elaine Ferguson; Marjorie Dehlinger; Donna Mildvan
Comparison of once-daily versus twice-daily combination antiretroviral therapy in treatment-naive patients: results of AIDS clinical trials group (ACTG) A5073, a 48-week randomized controlled trial.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2010;50(7):1041-52.
2009: Paul E Sax; Camlin Tierney; Ann C Collier; Margaret A Fischl; Katie Mollan; Lynne Peeples; Catherine Godfrey; Nasreen C Jahed; Laurie Myers; David Katzenstein; Awny Farajallah; James F Rooney; Belinda Ha; William C Woodward; Susan L Koletar; Victoria A Johnson; P Jan Geiseler; Eric S Daar
Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy.
The New England journal of medicine 2009;361(23):2230-40.
2009: Robert Gross; Camlin Tierney; Adriana S A Andrade; Christina Lalama; Susan Rosenkranz; Susan H Eshleman; Timothy Flanigan; Jorge Santana; Nadim Salomon; Ronald Reisler; Ilene Wiggins; Evelyn Hogg; Charles Flexner; Donna Mildvan
Modified directly observed antiretroviral therapy compared with self-administered therapy in treatment-naive HIV-1-infected patients: a randomized trial.
Archives of internal medicine 2009;169(13):1224-32.
2008: Ann C Collier; Camlin Tierney; Gerald F Downey; Susan H Eshleman; Angela D M Kashuba; Karin Klingman; Emanuel N Vergis; Gary E Pakes; James F Rooney; Alex Rinehart; John W Mellors
Randomized study of dual versus single ritonavir-enhanced protease inhibitors for protease inhibitor-experienced patients with HIV.
HIV clinical trials 2008;9(2):91-102.
2007: Nimalie D Stone; Shelia B Dunaway; Charles Flexner; Camlin Tierney; Gary Calandra; Stephen Becker; YING-JUN CAO; Ilene P Wiggins; Jeanne Conley; Ronald T MacFarland; Jeong-Gun Park; Christina Lalama; Snyder Sally; Beatrice Kallungal; Karin L Klingman; Craig W Hendrix
Multiple-dose escalation study of the safety, pharmacokinetics, and biologic activity of oral AMD070, a selective CXCR4 receptor inhibitor, in human subjects.
Antimicrobial agents and chemotherapy 2007;51(7):2351-8.
2006: Adriana Weinberg; Camlin Tierney; Michelle A Kendall; Ronald J Bosch; Julie Patterson-Bartlett; Alejo Erice; Martin S Hirsch; Bruce Polsky
Cytomegalovirus-specific immunity and protection against viremia and disease in HIV-infected patients in the era of highly active antiretroviral therapy.
The Journal of infectious diseases 2006;193(4):488-93.
2006: Heather J Ribaudo; David W Haas; Camlin Tierney; Richard B Kim; Grant R Wilkinson; Roy M Gulick; David B Clifford; Catia Marzolini; Courtney V Fletcher; Karen T Tashima; Daniel R Kuritzkes; Edward P Acosta
Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2006;42(3):401-7.
2005: Angela D M Kashuba; Camlin Tierney; Gerald F Downey; Edward P Acosta; Emanuel N Vergis; Karin L Klingman; John W Mellors; Susan H Eshleman; Trevor R Scott; Ann C Collier
Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results.
AIDS (London, England) 2005;19(2):145-52.
2004: David W Haas; Heather J Ribaudo; Richard B Kim; Camlin Tierney; Grant R Wilkinson; Roy M Gulick; David B Clifford; Todd Hulgan; Catia Marzolini; Edward P Acosta
Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study.
AIDS (London, England) 2004;18(18):2391-400.
2003: Alejo Erice; Camlin Tierney; M Hirsch; Angela M Caliendo; Adriana Weinberg; Michelle A Kendall; Bruce Polsky
Cytomegalovirus (CMV) and human immunodeficiency virus (HIV) burden, CMV end-organ disease, and survival in subjects with advanced HIV infection (AIDS Clinical Trials Group Protocol 360).
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2003;37(4):567-78.
2003: Camlin Tierney; Janet L Lathey; Cindy Christopherson; Daniel M Bettendorf; Richard T D'Aquila; Scott M Hammer; David A Katzenstein
Prognostic value of baseline human immunodeficiency virus type 1 DNA measurement for disease progression in patients receiving nucleoside therapy.
The Journal of infectious diseases 2003;187(1):144-8.
2002: Richard B Pollard; Camlin Tierney; Diane V Havlir; Pablo Tebas; Lawrence Fox; Laura M Smeaton; Douglas Richman; Gerald H Friedland
A phase II randomized study of the virologic and immunologic effect of zidovudine + stavudine versus stavudine alone and zidovudine + lamivudine in patients with >300 CD4 cells who were antiretroviral naive (ACTG 298).
AIDS research and human retroviruses 2002;18(10):699-704.
2001: Janet L Lathey; Camlin Tierney; S Y Chang; Richard T D'Aquila; D M Bettendorf; H C Alexander; C D Santini; A M Hughes; Charlene F Barroga; Stephen A Spector; J E Landes; Scott M Hammer; David A Katzenstein
Associations of CCR5, CCR2, and stromal cell-derived factor 1 genotypes with human immunodeficiency virus disease progression in patients receiving nucleoside therapy.
The Journal of infectious diseases 2001;184(11):1402-11.
2000: Peter B Gilbert; Heather J Ribaudo; L Greenberg; G Yu; Ronald J Bosch; Camlin Tierney; Daniel R Kuritzkes
Considerations in choosing a primary endpoint that measures durability of virological suppression in an antiretroviral trial.
AIDS (London, England) 2000;14(13):1961-72.
2000: Diane V Havlir; Camlin Tierney; G H Friedland; Richard B Pollard; Laura M Smeaton; JP Sommadossi; L Fox; H Kessler; K H Fife; Douglas D Richman
In vivo antagonism with zidovudine plus stavudine combination therapy.
The Journal of infectious diseases 2000;182(1):321-5.
1998: Keith Henry; Alejo Erice; Camlin Tierney; Henry H Balfour; Margaret A Fischl; A Kmack; S H Liou; A Kenton; Martin S Hirsch; J Phair; A Martinez; J O Kahn
A randomized, controlled, double-blind study comparing the survival benefit of four different reverse transcriptase inhibitor therapies (three-drug, two-drug, and alternating drug) for the treatment of advanced AIDS. AIDS Clinical Trial Group 193A Study Team.
Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association 1998;19(4):339-49.
1997: Rebecca A Betensky; Camlin Tierney
An examination of methods for sample size recalculation during an experiment.
Statistics in medicine 1997;16(22):2587-98.